Marta Milà-Alomà, PhD, Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, gives an insight to the potential of future research into blood biomarkers in the diagnosis of early Alzheimer’s disease (AD). It is a field that is advancing rapidly and the results of numerous recent studies have been very promising. Most studies investigating biomarkers for AD have mixed cohorts of participants, however, data on middle aged cognitively unimpaired individuals are lacking. Findings to date require validation by further studies with similar cohorts, especially in terms of application of blood biomarkers in clinical trials and eventually clinical practice. Future studies should focus on investigating more diverse populations and considering how other variables and comorbidities can affect how blood biomarkers identify early AD. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
